184 studies found for:    Amyloidosis
Show Display Options
Rank Status Study
21 Recruiting A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
Condition: Amyloidosis
Interventions: Drug: GSK2398852;   Drug: GSK2315698
22 Recruiting Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
Condition: Cardiac Amyloidosis
Intervention: Drug: F-18 florbetapir PET
23 Recruiting Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: NEOD001
24 Completed Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Bortezomib;   Drug: dexamethasone;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation (ASCT);   Drug: Melphalan
25 Recruiting Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
Condition: Amyloidosis
Interventions: Drug: KIACTA (eprodisate disodium);   Drug: Placebo
26 Completed Radioimmunoimaging of AL Amyloidosis
Condition: Primary Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
27 Completed Radioimmunoimaging of Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
28 Recruiting A Trial for Systemic Light-chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: BMDex
29 Completed Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Drug: Dexamethasone
30 Not yet recruiting Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain Amyloidosis
Condition: Primary Systemic Amyloidosis
Intervention: Drug: Doxycycline
31 Completed A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: Lenalidomide
32 Recruiting High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Device: High Cut-off Hemodialysis;   Drug: Chemotherapy
33 Completed Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Conditions: Secondary (AA) Amyloidosis;   Rheumatoid Arthritis;   Nephrotic Syndrome;   Familial Mediterranean Syndrome;   Kidney Diseases;   Gastrointestinal Diseases
Intervention: Drug: NC-503 (Anti-amyloidotic (AA) Agent)
34 Recruiting Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Intervention: Drug: Pomalidomide and Dexamethasone
35 Unknown  Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias);   Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
36 Recruiting Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
Condition: Primary Systemic Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
37 Completed Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
Condition: Primary Systemic Amyloidosis (AL)
Interventions: Drug: Melphalan;   Drug: Dexamethasone;   Procedure: Autologous stem cell transplantation
38 Recruiting Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Condition: Relapsed or Refractory Amyloidosis
Intervention: Drug: Chimeric (Ch) monoclonal anti-body (mAb) 11-1F4
39 Active, not recruiting Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Conditions: Primary Systemic Amyloidosis;   Light Chain Deposition Disease
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: melphalan;   Genetic: microarray analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
40 Recruiting A Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)
Conditions: Light Chain (AL) Amyloidosis;   Cardiac Involvement
Intervention: Drug: Epigallocatechin-3-gallate (EGCG)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years